Special Issue

Neonatal Infection: Antibiotics for Prevention and Treatment

Message from the Guest Editors

Infections, particularly bacterial sepsis, represent a leading cause of death and healthcare resource consumption across all age groups. Premature newborns are particularly vulnerable due to their immature immune systems and the necessity for invasive treatments. Timely antibiotic administration is critical in reducing sepsis mortality in newborns and children. However, diagnostic complexities often result in excessive antibiotic use, leading to the emergence of antibiotic-resistant microorganisms. The tracking of changes in neonatal sepsis prevention and treatment is also hindered by inconsistent definitions. The diagnosis of organ dysfunction in newborns and preterm infants presents significant challenges due to the absence of baseline values. This complexity further complicates the identification of sepsis in this population.

This Special Issue will address neonatal infections, including bacterial and fungal sepsis, epidemiology, definitions, severity scores, antibiotic use, biomarkers, new antibiotics, antibiotic stewardship, multi-resistance in microorganisms, and challenging infections.

Guest Editors

Prof. Dr. Cinzia Auriti

Departmental Faculty of Medicine, Saint Camillus International University for Health and Medical Sciences (Unicamillus), Via S. Alessandro 8, 00131 Rome, Italy

Dr. Maria Paola Ronchetti

Neonatal Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Piazza S. Onofrio 4, 00165 Rome, Italy

Deadline for manuscript submissions

30 November 2025



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/235235

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

